Area of research
Astronomy and Astrophysics · Instrumentation
Research interest
Research focused on Discontinuation and Ibrutinib, with related work in Venetoclax, Chronic lymphocytic leukemia, Adverse effect. Notable publications include 'Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency', 'First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era', and 'Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first line ibrutinib: a nationwide registry study from the Italian Medicines Agency'.
Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency
First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first line ibrutinib: a nationwide registry study from the Italian Medicines Agency
First-line Treatment of the Older Patients with CLL: A New Approach in the Chemo-free Era